LU92939I2 - Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable - Google Patents

Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable Download PDF

Info

Publication number
LU92939I2
LU92939I2 LU92939C LU92939C LU92939I2 LU 92939 I2 LU92939 I2 LU 92939I2 LU 92939 C LU92939 C LU 92939C LU 92939 C LU92939 C LU 92939C LU 92939 I2 LU92939 I2 LU 92939I2
Authority
LU
Luxembourg
Prior art keywords
isavuconazonium
salt
isavuconbazole
sulphate
hydrate
Prior art date
Application number
LU92939C
Other languages
English (en)
French (fr)
Original Assignee
Basilea Pharmaceutica Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Int Ltd filed Critical Basilea Pharmaceutica Int Ltd
Publication of LU92939I2 publication Critical patent/LU92939I2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
LU92939C 1999-11-02 2016-01-06 Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable LU92939I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121694 1999-11-02
EP00992946A EP1280795B1 (en) 1999-11-02 2000-10-25 N-substituted carbamoyloxyalkyl-azolium derivatives
PCT/EP2000/010524 WO2001032652A2 (en) 1999-11-02 2000-10-25 N-substituted carbamoyloxyalkyl-azolium derivatives

Publications (1)

Publication Number Publication Date
LU92939I2 true LU92939I2 (fr) 2016-03-07

Family

ID=8239312

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92939C LU92939I2 (fr) 1999-11-02 2016-01-06 Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable

Country Status (22)

Country Link
EP (1) EP1280795B1 (cs)
JP (1) JP3787307B2 (cs)
KR (1) KR100449797B1 (cs)
CN (1) CN1185230C (cs)
AR (1) AR029403A1 (cs)
AT (1) ATE291575T1 (cs)
AU (1) AU777859B2 (cs)
BE (1) BE2016C007I2 (cs)
BR (1) BRPI0015254C1 (cs)
CA (2) CA2388320C (cs)
CY (1) CY2016002I1 (cs)
DE (1) DE60018989T2 (cs)
DK (1) DK1280795T3 (cs)
ES (1) ES2238341T3 (cs)
FR (1) FR15C0096I2 (cs)
LU (1) LU92939I2 (cs)
MX (1) MXPA02004145A (cs)
NL (1) NL300791I2 (cs)
PT (1) PT1280795E (cs)
TR (1) TR200201205T2 (cs)
WO (1) WO2001032652A2 (cs)
ZA (1) ZA200203003B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
BRPI0815595B8 (pt) 2007-08-21 2021-05-25 Basilea Pharmaceutica Ag composição antifúngica para administração oral, que é autoemulsificante em contato com uma fase aquosa, seu uso e produto farmacêutico
AU2012272804B2 (en) 2011-06-22 2017-07-06 Vyome Therapeutics Limited Conjugate-based antifungal and antibacterial prodrugs
EA201592236A1 (ru) 2013-06-04 2016-06-30 Вайом Байосайнсиз Пвт. Лтд. Частицы с нанесенным покрытием и композиции, включающие такие частицы
CN104230894B (zh) * 2013-06-06 2016-08-24 南京华威医药科技开发有限公司 三唑类化合物
BR122019026066B1 (pt) 2014-12-30 2022-01-18 Dow Agrosciences Llc Compostos de picolinamida
CN106032356B (zh) * 2015-03-13 2018-09-14 江苏正大丰海制药有限公司 一种[n-甲基-吡啶-2-基]氨基甲酸-1-氯乙酯的制备方法
CN104974143A (zh) * 2015-05-12 2015-10-14 深圳致君制药有限公司 一种季铵盐类化合物、其制备方法以及用途
CN106467519B (zh) * 2015-08-17 2019-08-13 南京华威医药科技集团有限公司 一种水溶性三唑化合物
CN106467534B (zh) * 2015-08-17 2019-10-11 江苏奥赛康药业有限公司 一种硫酸艾沙康唑鎓化合物及其药物组合物
CN106565699B (zh) * 2015-10-10 2019-07-26 江苏正大丰海制药有限公司 一种艾沙康唑硫酸盐晶体及其制备方法
WO2018067702A1 (en) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Bottlebrush copolymers and uses thereof
CN108456194B (zh) * 2017-02-17 2021-06-22 武汉朗来科技发展有限公司 三氮唑抗菌衍生物、其药物组合物和用途
CN106916152B (zh) * 2017-04-27 2019-09-17 扬子江药业集团有限公司 氧化还原反应制备艾沙康唑鎓单硫酸盐的方法
CA3068318A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology Branched multi-functional macromonomers and related polymers and uses thereof
WO2019006425A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology IMAGING AGENTS OF BRUSH ARRAY STAR POLYMERS AND USES THEREOF
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
CN110317165A (zh) * 2018-03-28 2019-10-11 上海医药工业研究院 一种药物中间体2-甲胺基-3-吡啶甲醇的制备方法
US12414997B2 (en) 2018-04-13 2025-09-16 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
CN110551064B (zh) * 2018-06-01 2021-01-01 重庆世森医药科技有限公司 艾沙康唑硫酸酯及其中间体的制备方法
US12428414B2 (en) 2018-08-01 2025-09-30 Basilea Pharmaceutica International AG Methods for purifying isavuconazonium sulfate
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
CN110128420A (zh) * 2019-05-08 2019-08-16 阴启明 硫酸氢根/硫酸根型阴离子交换技术制备艾沙康唑鎓单硫酸盐的方法
EP4021576A1 (en) 2019-08-26 2022-07-06 Synthon B.V. Isavuconazonium salts and process for preparing thereof
KR20220085791A (ko) * 2019-10-16 2022-06-22 메사추세츠 인스티튜트 오브 테크놀로지 브러시 전구약물 및 그의 용도
US12042513B2 (en) 2020-01-10 2024-07-23 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof
JP7570382B2 (ja) 2021-09-28 2024-10-21 旭化成ファーマ株式会社 エアベント付き輸液フィルタを備える点滴静脈投与用輸液セット
JP7454905B2 (ja) * 2021-09-28 2024-03-25 旭化成ファーマ株式会社 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び/又は予防剤
CN118679145A (zh) 2021-12-20 2024-09-20 麻省理工学院 用于递送药剂的生物分子-聚合物-药剂缀合物
EP4289840A1 (en) 2022-06-07 2023-12-13 Zaklady Farmaceutyczne Polpharma S.A. A process for preparing isavuconazonium sulfate
WO2024094329A1 (en) 2022-11-01 2024-05-10 Basilea Pharmaceutica International Ag, Allschwil Blister-packaged capsule preparation containing isavuconazonium sulfate
WO2024189550A1 (en) * 2023-03-13 2024-09-19 Apitoria Pharma Private Limited Process for the preparation of isavuconazonium sulfate and its crystalline forms
WO2025114603A1 (en) 2023-11-30 2025-06-05 Basilea Pharmaceutica International Ag, Allschwil Pharmaceutical combinations for use in the treatment of fungal infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3108997B2 (ja) * 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
CA2281875A1 (en) * 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
WO1999045008A1 (en) * 1998-03-06 1999-09-10 F. Hoffmann-La Roche Ag 3-[4-(4-cyanophenyl)thiazol-2-y)]-1-(1h-1,2,4-triazol-1-yl)-butan-2-ol derivatives having antifungal activity

Also Published As

Publication number Publication date
CA2388320C (en) 2009-12-15
EP1280795A2 (en) 2003-02-05
WO2001032652A2 (en) 2001-05-10
BR0015254A (pt) 2002-06-25
CN1387529A (zh) 2002-12-25
DE60018989T2 (de) 2005-08-18
DE60018989D1 (de) 2005-04-28
JP3787307B2 (ja) 2006-06-21
TR200201205T2 (tr) 2002-08-21
CN1185230C (zh) 2005-01-19
CA2388320A1 (en) 2001-05-10
EP1280795B1 (en) 2005-03-23
NL300791I1 (cs) 2016-03-15
CA2680292C (en) 2012-11-27
BR0015254B1 (pt) 2013-05-21
FR15C0096I2 (fr) 2016-04-22
CY2016002I2 (el) 2016-10-05
CA2680292A1 (en) 2001-05-10
BRPI0015254C1 (pt) 2021-05-25
AU2835201A (en) 2001-05-14
ES2238341T9 (es) 2016-03-02
MXPA02004145A (es) 2002-10-17
ATE291575T1 (de) 2005-04-15
KR100449797B1 (ko) 2004-09-30
KR20020062298A (ko) 2002-07-25
WO2001032652A3 (en) 2001-11-15
BE2016C007I2 (cs) 2019-10-23
DK1280795T3 (da) 2005-07-18
BRPI0015254B8 (pt) 2017-04-25
PT1280795E (pt) 2005-06-30
CY2016002I1 (el) 2016-10-05
FR15C0096I1 (cs) 2016-02-12
AU777859B2 (en) 2004-11-04
JP2003513090A (ja) 2003-04-08
NL300791I2 (cs) 2016-03-15
AR029403A1 (es) 2003-06-25
ZA200203003B (en) 2003-09-23
ES2238341T3 (es) 2005-09-01

Similar Documents

Publication Publication Date Title
LU92939I2 (fr) Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable
LU91681I2 (fr) "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"
NO2020019I1 (no) Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
DE69916094D1 (de) Dispersionen mit verbesserter stabilität
MA26641A1 (fr) Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments
NO20013953D0 (no) Dreibart kontrollhode innvendig i stigeror
IS1812B (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
DE3772883D1 (de) Hydrophob modifizierte hydroxyethylcellulose in waesserigen dispersionen.
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
FI990144L (fi) Propulsioyksikön kääntäminen
IL143349A0 (en) Azepinoindole derivatives, the production and use thereof
PL356705A1 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid
EP1293131A4 (en) MEANS FOR CLEANING TREATMENT
HUP0102946A3 (en) Composition comprising at least one uv screening agent and a flavynium salt which is unsubstituted in position 3, for colouring the skin and use its
FR2854795B1 (fr) Composition cosmetique visant a creer une variation de couleur avec l'angle d'observation
IL165851A0 (en) The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury
IL152061A0 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
GB9921537D0 (en) The ultimate rig
NL300094I1 (nl) Combinatie van budeonide en formoterol, desgewenstin de vorm van een farmaceutisch aanvaardbaar zou t, ester en/of hydraat.
NO20011652L (no) Fremgangsmåte for fremstilling av 1,5-diaryl-3-substituerte pyrazoler
DE60023072D1 (de) Wässrige Dispersionen
Fraser Showstopper.